Entrada Therapeutics Inc (TRDA)

Entrada Therapeutics' stock has experienced fluctuations over the past six months. While the stock price decreased by 47.41% over the last 12 months, it increased by 44.74% in the past month as of November 24, 2025. Key events include the Third Quarter 2025 financial results reporting a GAAP EPS loss of $-1.06 and collaboration revenue of $1.6 million, Roth/MKM reducing its price target to $17.00 from $21.00, the Fourth Quarter and Full Year 2024 financial results highlighting the FDA's removal of the clinical hold on ENTR-601-44 and MHRA authorization to initiate ELEVATE-44-201 in the U.K., and insider trading activity in November 2025.

Entrada Therapeutics does not have commercialized products that exhibit traditional demand seasonality. The company's revenue primarily comes from research and development activities and strategic collaborations, which are not inherently seasonal. Investor interest or clinical trial enrollment might have seasonality, but the provided information does not detail such patterns.

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for intracellular targets, utilizing its EEV platform for efficient therapeutic delivery. The company is advancing a portfolio targeting neuromuscular, ocular, rare genetic diseases, oncology, and immunology. Key product candidates include ENTR-601-44 (Phase 1 for DMD exon 44 skipping, clinical hold removed by FDA), VX-670 (Phase 1/2 for myotonic dystrophy type 1, collaboration with Vertex), ENTR-601-45 (regulatory filings submitted for global Phase 1/2 study for DMD exon 45 skipping), ENTR-601-50 (regulatory filing for UK clearance made in Q3 2025, EU clearance expected in H2 2026), ENTR-601-51 (global regulatory applications on track for submission in 2026), ENTR-001 (clinical trials for Wolfram syndrome and restoring lysosomal function in DMD), and EN301 (developed for other lysosomal storage diseases).

Entrada Therapeutics, Inc. is headquartered in Boston, Massachusetts, and was incorporated in 2016. The company's operations are expanding globally, with regulatory filings pursued in international markets, including authorization from the U.K.'s MHRA and planned EU submissions for its DMD programs.

Entrada Therapeutics has a reputation as a biopharmaceutical company focused on unmet medical needs through innovative technology. The company is recognized for its pioneering work in intracellular therapeutics and its commitment to developing therapies for severe diseases. As of November 24, 2025, Entrada Therapeutics has received a "Strong Buy" consensus rating from analysts, with a 12-month average price target of $24.50. Positive data and regulatory authorizations for its clinical programs contribute positively to its scientific and developmental reputation. Strategic collaborations, such as the research collaboration and license agreement with Vertex, have validated Entrada's technology and provided financial support. The DREAMS Grant Program enhances its reputation within the patient community.

The ownership of Entrada Therapeutics is distributed among institutional investors, individual shareholders, and company insiders. Institutional investors hold a significant portion of the stock, ranging from approximately 77.41% to 87.42%. Insiders hold a substantial percentage, with figures around 60.06% to 89.82%. Individual/retail investors hold a smaller percentage, with figures around 7.58% to 17.67%.